Complex Regional Pain Syndrome (previously known as reflex sympathetic dystrophy, RSD) is a condition presenting with burning, nondermatomal pain associated with hyperhidrosis, intermittent oedema and discolouration and with evidence of mechanical and thermal allodynia. Conventional treatment is with sympathetic blockade produced by local anaesthetic injection around the appropriate sympathetic ganglia or by the use of agents depleting the sympathetic nerve endings of noradrenaline (eg intravenous regional sympathetic block with guanethidine). In a relatively small percentage of cases treatment is not effective. Phentolamine mesylate has been shown to be useful in diagnosing pains with a sympathetic component' but to date this has not been used for treatment by the oral route for this condition. CASE REPORT A 32 year old male presented with a 2 month history of burning, nondermatomal pain affecting the right lower leg following a soft tissue injury precipitated by a fall. In addition to pain he had intermittent oedema, blue discolouration, hyperhidrosis and mechanical and thermal allodynia. Radiographic examination failed to reveal any abnormality. Simple analgesics failed to control his pain but it was completely although temporarily relieved for 48 hours by an intravenous bolus of 15 mg phentolamine mesylate. A diagnosis of complex regional pain syndrome type 1 (at that time known as reflex sympathetic dystrophy) was made. Subsequently a lumbar sympathectomy using phenol was performed under radiographic control. This relieved the discomfort for 6 weeks. When the pain returned it was not amenable to nonsteroidal or simple analgesics and indeed repeat chemical lumbar sympathectomy produced no relief. This patient attended the clinic every 3 days and was given phentolamine mesylate 20 mg intravenously which relieved pain for 2 days. After 10 months of intravenous therapy as described a dose of 20 mg phentolamine was given orally on a daily basis (the content of the ampoule was emptied into a glass of water). This gave consistent pain relief over a 24 hour period. The regime has been maintained for the three month period leading up to this report. Despite its effect on peripheral alpha receptors, treatment with short acting alpha antagonist phentolamine mesylate is not associated with significant hypotension or reflex tachycardia.2 Orally active alpha antagonists are available (for example phenoxybenzamine) but these seem to be less active against sympathetically maintained pain and have a greater hypotensive effect. Oral use ofphentolamine is not appropriate as a routine treatment, but may be useful in the diagnosis and the treatment of the small group of patients in whom conventional treatment is unsuccessful but who are responsive to phentolamine. Phentolamine mesylate has been used orally in those with erectile impotence3' 4 but has not been described before for the treatment of those with complex regional pain syndrome.
